Analyst Reco. BioNTech SE

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
87.21 ^USD	+0.58%		+0.46%	-17.37%

Apr. 25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
Apr. 25	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

BIONTECH : Gets a Neutral rating from Deutsche Bank	Apr. 23	ZD
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	Mar. 27	MT
BIONTECH : Deutsche Bank remains Neutral	Mar. 22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	Mar. 21	MT
BIONTECH : A miss is a miss	Mar. 21
BIONTECH : Deutsche Bank reaffirms its Neutral rating	Mar. 21	ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating	Mar. 21	ZD
BIONTECH : Jefferies sticks Neutral	Mar. 20	ZD
BIONTECH : UBS gives a Neutral rating	Mar. 20	ZD
BMO Capital Initiates Coverage on BioNTech With Outperform Rating, $127 Price Target	Feb. 23	MT
Canaccord Genuity Adjusts Price Target on BioNTech to $171 From $168, Maintains Buy Rating	Feb. 20	MT
HC Wainwright Adjusts BioNTech Price Target to $107 From $133, Maintains Buy Rating	Jan. 23	MT
WHO sees 'incredibly low' COVID, flu vaccination rates as cases surge	Jan. 12	RE
BIONTECH : UBS sticks Neutral	Jan. 09	ZD
Oppenheimer Initiates BioNTech With Perform Rating	Jan. 05	MT
BIONTECH : UBS gives a Neutral rating	Dec. 14	ZD
BIONTECH : Jefferies remains Neutral	Dec. 12	ZD
Morgan Stanley Lifts Price Target on BioNTech to $112 From $111, Keeps Equalweight Rating	Dec. 12	MT
JPMorgan Chase Downgrades BioNTech to Underweight From Neutral, Cuts Price Target to $99 From $106	Dec. 01	MT
BIONTECH : UBS sticks Neutral	Nov. 28	ZD

No results for this search

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT